Santen Pharmaceutical (OTCMKTS:SNPHY) Shares Gap Up – Still a Buy?

Shares of Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) gapped up before the market opened on Wednesday . The stock had previously closed at $10.34, but opened at $11.5380. Santen Pharmaceutical shares last traded at $11.5380, with a volume of 354 shares trading hands.

Wall Street Analysts Forecast Growth

Separately, Zacks Research upgraded shares of Santen Pharmaceutical to a “hold” rating in a research report on Monday, April 13th. One investment analyst has rated the stock with a Hold rating, According to MarketBeat, the stock presently has a consensus rating of “Hold”.

Santen Pharmaceutical Trading Up 10.3%

The firm has a market capitalization of $3.68 billion and a P/E ratio of 0.10. The stock has a 50-day simple moving average of $10.86 and a two-hundred day simple moving average of $10.69.

About Santen Pharmaceutical

Santen Pharmaceutical Co, Ltd. is a Japan?based specialty pharmaceutical company focused exclusively on ophthalmology. Headquartered in Osaka, Santen engages in the research, development, manufacture and marketing of prescription and over?the?counter products for the diagnosis and treatment of eye diseases. Its core product portfolio includes therapies for glaucoma, dry eye, retinal disorders, uveitis and post?operative care, as well as surgical equipment and diagnostic agents designed to support comprehensive eye care.

With roots tracing back to the late 19th century, Santen has grown from a domestic manufacturer to a global ophthalmic specialist.